Dose-Response Curve: Interventions to Prevent and Treat Radiodermatitis

Overview

Dose response curve to define the security and tolerable dose to be used for prevention and treatment of radiodermatitis in patients with breast or head and neck cancer.

Full Title of Study: “Use of Chamomilla Recutita Gel and Urea Cream to Prevent and Treat Radiodermatitis: Phase 2 Study”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Masking: Double (Participant, Outcomes Assessor)
  • Study Primary Completion Date: March 2015

Detailed Description

The study is being conducted in Center for High Complexity Oncology (CACON) located at the University Hospital of Brasília (HUB). Has as its target population subjects diagnosed with breast and head and neck cancer undergoing radiotherapy. Three doses of urea cream are being tested. Participants are subjected to simple randomization technique, in which the members of the study are directly allocated in groups set forth, without any intermediate step. Patients are identified, go to a nursing consultation for general orientations about treatment. After the consultation, patients are invited to participate in the study. The patient should express its acceptance through the informed consent form. Data are being collected through interviews and medical records. Patients are being evaluated during three weeks, considering the toxicity of the intervention and the beginning of radiodermatitis. To evaluate the skin reaction will be applied scale of the Radiation Therapy Oncology Group (RTOG) – Acute Radiation Morbidity Scoring Criteria, Common Terminology Criteria for Adverse Events (CTCAE) and Radiation-Induced Skin Reaction Assessment Scale (RISRAS). For reliable assessment and record of the evolution throughout the treatment and study, patients will be photographed weekly (D0, D5, D10, D15). Will be photographed major regions subject to evaluation: frontal, right side profile and left side profile with Photographic camera Nikon P510. The data will be inserted into Statistical Package for Social Sciences (SPSS), version 18.0, for the analysis.

Interventions

  • Drug: Urea Dose A
    • Urea cream for topical use.
  • Drug: Urea Dose B
    • Urea cream for topical use.
  • Drug: Urea Dose C
    • Urea cream for topical use.
  • Drug: Chamomile Dose A
    • Chamomile gel for topical use.
  • Drug: Chamomile Dose B
    • Chamomile gel for topical use.
  • Drug: Chamomile Dose C
    • Chamomile gel for topical use.

Arms, Groups and Cohorts

  • Experimental: Urea Dose A
    • Topical application of the urea cream in concentration A. The product should be applied on the skin three times daily over 3 weeks.
  • Experimental: Urea Dose B
    • Topical application of the urea cream in concentration B. The product should be applied on the skin three times daily over 3 weeks.
  • Experimental: Urea Dose C
    • Topical application of the urea cream in concentration C. The product should be applied on the skin three times daily over 3 weeks.
  • Experimental: Chamomile Dose A
    • Topical application of chamomile recutita gel in concentration A. The product should be applied on the skin three times daily over 3 weeks.
  • Experimental: Chamomile Dose B
    • Topical application of chamomile recutita gel in concentration B. The product should be applied on the skin three times daily over 3 weeks.
  • Experimental: Chamomile Dose C
    • Topical application of chamomile recutita gel in concentration C. The product should be applied on the skin three times daily over 3 weeks.

Clinical Trial Outcome Measures

Primary Measures

  • Time of occurrence of Radiodermatitis
    • Time Frame: 3 weeks
    • Time of occurrence of Radiodermatitis according with the Radiation Therapy Oncology Group (RTOG).

Secondary Measures

  • Indicators of toxicity
    • Time Frame: 3 weeks
    • Evaluate the tolerance and safety of the intervention according to the assessment of toxicity during the intervention. To evaluate the toxicity will be considered signs and symptoms referable to the region of application of the product, such as skin rash, urticaria, vesicles, blisters, pustules, as well as the patient’s report of discomfort, burning, stinging and itching.

Participating in This Clinical Trial

Inclusion Criteria

  • Being an adult, over the age of 18 years old – Owning diagnosis of breast or head and neck cancer – Being first referred to the radiotherapy protocol – Have absence of radiodermatitis and integrates skin to start radiotherapy – Not have presented anticipated reaction of hypersensitivity to chamomile or any plant of the family Asteraceae or Compositae or urea. – Demonstrate conditions to continue the intervention in their home environment when needed. Exclusion Criteria:

  • Medical prescription for the procedure of data collection, some kind of intervention to prevent radiodermatitis.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of Brasilia
  • Collaborator
    • University of Washington
  • Provider of Information About this Clinical Study
    • Principal Investigator: Elaine Barros Ferreira, RN, University of Brasilia – University of Brasilia
  • Overall Official(s)
    • Paula Elaine D Reis, RN PhD, Study Director, University of Brasilia
    • Marcia A Ciol, PhD, Study Director, University of Washington

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.